These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 26597881)

  • 1. Inhibition of Mast Cell-Derived Histamine Decreases Human Cholangiocarcinoma Growth and Differentiation via c-Kit/Stem Cell Factor-Dependent Signaling.
    Johnson C; Huynh V; Hargrove L; Kennedy L; Graf-Eaton A; Owens J; Trzeciakowski JP; Hodges K; DeMorrow S; Han Y; Wong L; Alpini G; Francis H
    Am J Pathol; 2016 Jan; 186(1):123-33. PubMed ID: 26597881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Function of mast cell and bile-cholangiocarcinoma interplay in cholangiocarcinoma microenvironment.
    Shi A; Liu Z; Fan Z; Li K; Liu X; Tang Y; Hu J; Li X; Shu L; Zhao L; Huang L; Zhang Z; Lv G; Zhang Z; Xu Y
    Gut; 2024 Jul; 73(8):1350-1363. PubMed ID: 38458750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking H1/H2 histamine receptors inhibits damage/fibrosis in Mdr2
    Kennedy L; Hargrove L; Demieville J; Karstens W; Jones H; DeMorrow S; Meng F; Invernizzi P; Bernuzzi F; Alpini G; Smith S; Akers A; Meadows V; Francis H
    Hepatology; 2018 Sep; 68(3):1042-1056. PubMed ID: 29601088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of mast cell-derived histamine secretion by cromolyn sodium treatment decreases biliary hyperplasia in cholestatic rodents.
    Kennedy LL; Hargrove LA; Graf AB; Francis TC; Hodges KM; Nguyen QP; Ueno Y; Greene JF; Meng F; Huynh VD; Francis HL
    Lab Invest; 2014 Dec; 94(12):1406-18. PubMed ID: 25365204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The H4 histamine receptor agonist, clobenpropit, suppresses human cholangiocarcinoma progression by disruption of epithelial mesenchymal transition and tumor metastasis.
    Meng F; Han Y; Staloch D; Francis T; Stokes A; Francis H
    Hepatology; 2011 Nov; 54(5):1718-28. PubMed ID: 21793031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of histidine decarboxylase ablates the autocrine tumorigenic effects of histamine in human cholangiocarcinoma.
    Francis H; DeMorrow S; Venter J; Onori P; White M; Gaudio E; Francis T; Greene JF; Tran S; Meininger CJ; Alpini G
    Gut; 2012 May; 61(5):753-64. PubMed ID: 21873469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silencing of LAMC2 Reverses Epithelial-Mesenchymal Transition and Inhibits Angiogenesis in Cholangiocarcinoma via Inactivation of the Epidermal Growth Factor Receptor Signaling Pathway.
    Pei YF; Liu J; Cheng J; Wu WD; Liu XQ
    Am J Pathol; 2019 Aug; 189(8):1637-1653. PubMed ID: 31345467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway.
    Visciano C; Liotti F; Prevete N; Cali' G; Franco R; Collina F; de Paulis A; Marone G; Santoro M; Melillo RM
    Oncogene; 2015 Oct; 34(40):5175-86. PubMed ID: 25619830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mast cells selectively target large cholangiocytes during biliary injury via H2HR-mediated cAMP/pERK1/2 signaling.
    Zhou T; Meadows V; Kundu D; Kyritsi K; Owen T; Ceci L; Carpino G; Onori P; Gaudio E; Wu N; Glaser S; Ekser B; Alpini G; Kennedy L; Francis H
    Hepatol Commun; 2022 Oct; 6(10):2715-2731. PubMed ID: 35799467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mast Cells Induce Ductular Reaction Mimicking Liver Injury in Mice Through Mast Cell-Derived Transforming Growth Factor Beta 1 Signaling.
    Kyritsi K; Kennedy L; Meadows V; Hargrove L; Demieville J; Pham L; Sybenga A; Kundu D; Cerritos K; Meng F; Alpini G; Francis H
    Hepatology; 2021 Jun; 73(6):2397-2410. PubMed ID: 32761972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma.
    Cadamuro M; Nardo G; Indraccolo S; Dall'olmo L; Sambado L; Moserle L; Franceschet I; Colledan M; Massani M; Stecca T; Bassi N; Morton S; Spirli C; Fiorotto R; Fabris L; Strazzabosco M
    Hepatology; 2013 Sep; 58(3):1042-53. PubMed ID: 23505219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of mast cell-secreted histamine decreases biliary proliferation and fibrosis in primary sclerosing cholangitis Mdr2(-/-) mice.
    Jones H; Hargrove L; Kennedy L; Meng F; Graf-Eaton A; Owens J; Alpini G; Johnson C; Bernuzzi F; Demieville J; DeMorrow S; Invernizzi P; Francis H
    Hepatology; 2016 Oct; 64(4):1202-1216. PubMed ID: 27351144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of hepatic stem cell factor by Vivo-Morpholino treatment inhibits mast cell migration and decreases biliary damage/senescence and liver fibrosis in Mdr2
    Meadows V; Kennedy L; Hargrove L; Demieville J; Meng F; Virani S; Reinhart E; Kyritsi K; Invernizzi P; Yang Z; Wu N; Liangpunsakul S; Alpini G; Francis H
    Biochim Biophys Acta Mol Basis Dis; 2019 Dec; 1865(12):165557. PubMed ID: 31521820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FBXW7 suppresses epithelial-mesenchymal transition, stemness and metastatic potential of cholangiocarcinoma cells.
    Yang H; Lu X; Liu Z; Chen L; Xu Y; Wang Y; Wei G; Chen Y
    Oncotarget; 2015 Mar; 6(8):6310-25. PubMed ID: 25749036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetraspanin 1 promotes epithelial-to-mesenchymal transition and metastasis of cholangiocarcinoma via PI3K/AKT signaling.
    Wang Y; Liang Y; Yang G; Lan Y; Han J; Wang J; Yin D; Song R; Zheng T; Zhang S; Pan S; Liu X; Zhu M; Liu Y; Cui Y; Meng F; Zhang B; Liang S; Guo H; Liu Y; Hassan MK; Liu L
    J Exp Clin Cancer Res; 2018 Dec; 37(1):300. PubMed ID: 30514341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allicin Inhibits Proliferation and Invasion in Vitro and in Vivo via SHP-1-Mediated STAT3 Signaling in Cholangiocarcinoma.
    Chen H; Zhu B; Zhao L; Liu Y; Zhao F; Feng J; Jin Y; Sun J; Geng R; Wei Y
    Cell Physiol Biochem; 2018; 47(2):641-653. PubMed ID: 29794468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation and characterization of hepatic mast cells from cholestatic rats.
    Hargrove L; Graf-Eaton A; Kennedy L; Demieville J; Owens J; Hodges K; Ladd B; Francis H
    Lab Invest; 2016 Nov; 96(11):1198-1210. PubMed ID: 27548803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TCF21 inhibits tumor-associated angiogenesis and suppresses the growth of cholangiocarcinoma by targeting PI3K/Akt and ERK signaling.
    Duan HX; Li BW; Zhuang X; Wang LT; Cao Q; Tan LH; Qu GF; Xiao S
    Am J Physiol Gastrointest Liver Physiol; 2019 Jun; 316(6):G763-G773. PubMed ID: 30920845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bile exosomal miR-182/183-5p increases cholangiocarcinoma stemness and progression by targeting HPGD and increasing PGE2 generation.
    Shu L; Li X; Liu Z; Li K; Shi A; Tang Y; Zhao L; Huang L; Zhang Z; Zhang D; Huang S; Lian S; Sheng G; Yan Z; Zhang Z; Xu Y
    Hepatology; 2024 Feb; 79(2):307-322. PubMed ID: 37140231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-494-dependent WDHDI inhibition suppresses epithelial-mesenchymal transition, tumor growth and metastasis in cholangiocarcinoma.
    Liu B; Hu Y; Qin L; Peng XB; Huang YX
    Dig Liver Dis; 2019 Mar; 51(3):397-411. PubMed ID: 30314946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.